Inovio Pharmaceuticals INO shares are trading higher on Friday as traders circulate an article from Kansas City's KSHB 41 that reported the Center for Pharmaceutical Research is moving forward with trials of COVID-19 DNA vaccines developed by Inovio.
Inovio Pharmaceuticals is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Inovio shares were up 10.36% at $17.29 at the time of publication on Friday. The stock has a 52-week high of $33.79 and a 52-week low of $1.92.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
